This study investigated the role of neutrophils and the adaptor protein PSTPIP2 in human pediatric CRMO, comparing 34 CRMO patients (across untreated, NSAID, zoledronate, and anti-TNF treatment groups) to 20 healthy controls using flow cytometry, biochemical assays, and neutrophil transcriptomic profiling.
CRMO neutrophils showed chronic activation (reduced CD62L, p=0.0016) correlating with MRI lesion burden, and PSTPIP2 protein was consistently decreased (p=0.0006) despite elevated mRNA (p=0.0005), suggesting post-transcriptional regulation; both abnormalities normalized with anti-TNF therapy.
Transcriptomic profiling was limited to only 4 patients and 3 controls, reducing statistical power for pathway-level findings. The cross-sectional design limits causal inference. The study does not clarify the exact post-transcriptional mechanism driving PSTPIP2 protein loss.
Neutrophil activation markers (e.g., CD62L) and chemokines (CCL4, CCL4L2) may serve as disease activity biomarkers in pediatric CRMO. Anti-TNF therapy appears to reverse both neutrophil dysregulation and PSTPIP2 deficiency, providing a mechanistic rationale for its use in refractory cases.